Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to examine the impact of suvorexant, an FDA-approved insomnia
medication, on daytime symptoms (as measured by the Daytime Insomnia Symptoms Scale:
cognition, positive mood, negative mood, and fatigue/sleepiness) among older adults with
insomnia. The primary hypothesis is that relative to placebo, suvorexant will improve sleep
and daytime symptoms. The word "placebo" refers to a harmless pill with no therapeutic
effect.